Steric and electronic parameters of 4'-substituents play significant roles in steering the conformation of nucleoside analogues. In order to investigate the relationship of 4'-substituent with antiviral enhancement, novel 4'-phenyl-5'-norcarbocyclic adenosine phosphonic acid analogues were racemically synthesized via de novo acyclic stereoselective route from propionaldehyde 5. The phenyl substituted cyclopentenols 15a and 15b as key intermediates were successfully constructed via reiterative carbonyl addition of Grignard reagents and ring-closing metathesis of corresponding divinyl 14. The synthesized nucleoside phosphonic acids analogues 19, 20, 21, and 23 were subjected to antiviral screening against HIV-1.
Introduction
The development of new effective antiviral agent is essential for overcoming viral diseases, such as acquired immunodeficiency syndrome (AIDS) caused by human immunodeficiency virus (HIV). Recently, several branched nucleosides 1 have been synthesized and evaluated as potent antiviral agents. Among them, 4'-ethynylthymidine (1) 2 and 4'-vinylthymidine (2) 3 which have an additional triple or double bond at the 4'-position, were reported to have potent anti-HIV activities (Fig. 1) . Molecular modeling studies demonstrated the presence of a relatively hydrophobic 4'-pocket that can accommodate these substitutions, contributes to the observed enhancement in potency. 4 5'-Norcarbocyclic nucleoside phosphonic acid analogues such as 4'-ethynyl-cpAP (3) and 4'-vinyl-cpAP (4) 4 have encouraged the search for novel nucleosides in this class of compounds (Fig. 1) . 5 The phosphonate has certain advantages over its phosphate counterpart as it is metabolically stable because its phosphorus-carbon bond is not susceptible to hydrolytic cleavage. 6 Moreover, a phosphonate nucleoside analogue can skip the requisite first phosphorylation, which is a crucial step for the activation of nucleosides. This is frequently a limiting event in the phosphorylation sequence, which ultimately leads to triphosphates. 7 The spacial location of the oxygen atom, namely the β-position from the phosphorus atom in the nucleoside analogue, has been demonstrated to play a critical role for antiviral activity. This oxygen atom for antiviral activity may be attributed to the increased binding capacity of the phosphonate analogues to target enzymes. 8 Actually, the exact role of substituent in 4'-position in nucleoside analogues in inhibiting reverse transcriptase (RT) has not been explored clearly. In continuation of our effort to find more detailed structure activity relationship of branched nucleoside as RT inhibitor, we have designed and prepared a novel class of nucleosides comprising branched-5'-norcarbocyclic phosphonic acid analogues bearing phenyl group which has bigger van der Waals radius than ethynyl or ethenyl functional group.
As shown in Scheme 1, the target compounds were prepared from protected propionaldehyde, 5, which was readily synthesized from 1,3-propanediol using known procedure. 9 The aldehyde functional group of 5 was subjected to carbonyl addition reaction by phenylmagnesium bromide to give the secondary alcohol 6, which was subjected to oxidation condition using Corey-Kim's oxidation procedure 10 to provide corresponding ketone derivative 7. The ketone functional group of 7 was again subjected to addition reaction by vinylmagnesium bromide to give tertiary hydroxyl analogue 8.
In order to differentiate the two hydroxyl groups, the silicon protection group of the primary hydroxyl was replaced with a benzoyl group by sequential desilylation and benzoylation to provide 10. Silylation of the tertiary hydroxyl group of 10 was successfully accomplished using t- butyldimethylsilyl trifluoromethanesulfonate (TBDMSOTf, 2,6-lutidine) 11 to give the fully protected compound 11. Removal of the benzoyl protecting group of 11 under methanolic ammonium condition (NH 3 /MeOH) provided the primary alcohol 12, which was oxidized to the aldehyde 13 using Swern oxidation conditions (Oxalyl chloride, DMSO, TEA). 12 The aldehyde 13 was subjected to nucleophilic Grignard conditions with vinylmagnesium bromide to give divinyl 14 which was subjected to ring-closing metathesis (RCM) conditions using 2 nd generation Grubbs catalyst 13 to provide phenyl substituted cyclopentenol 15a (34%) and 15b (35%), which were readily separated by silica gel column chromatography. The NOE experiments with cyclopentenols 15a and 15b confirmed these assignments. Also, the exact structural determinations were performed in the latter stage of compounds 22 and 23 (Fig. 2) .
To synthesize the desired 5'-norcarbocyclic adenosine nucleoside analogues, the protected cyclopentenol 15b was treated with 6-chloropurine under Mitsunobu conditions 14 (DIAD and PPh 3 ). Slow addition of diisopropyl azodicarboxylate (DIAD) to a mixture of cyclopentenol 15b, triphenylphosphine and the 6-chloropurine in anhydrous tetrahydrofuran (THF) gave a yellow solution which was stirred for 3 h at −10 °C to give the 6-chloropurine analogue 16 (Scheme 2).
15 The silicon protection group was removed with tetrabutylammonium fluoride (TBAF) to provide 5'-norcarbocyclic nucleoside analogue 17. plished with a catalytic amount of osmium tetraoxide (OsO 4 ) and 4-methyl-morpholine N-oxide (NMO) as an oxidant to give the dihydroxylated isomer 21 (32%) and 22 (30%) with almost equal amount (Scheme 3). 19 A complete NOE study allowed an unambiguous determination of their respective stereochemistry (Fig. 2) . For compound 22, strong NOE of H-1' ↔ H-2' as well as H-1' ↔ H-3', which showed 1',2',3'-cis relationships, was observed. According to this result, 2'-and 3'-hydroxyl groups of 22 were located on the b face. On the other hand, for 21 compound, weak NOE, such as H-1' ↔ H-2' and H-1' ↔ H-3', were assigned to the 1',2'-and 1',3'-trans relationships and a face stereochemicals of 2'-and 3'-hydroxyl groups. Hydrolysis of diethyl phosphonate functional groups of 21 by the similar procedure described for 20 gave an adenosine phosphonic acid derivative 23.
The synthesized nucleoside phosphonate and phosphonic acid analogues 19, 20, 21 and 23 were then evaluated for antiviral activity against human immunodeficiency virus. The procedures for measuring the antiviral activity toward wild-type HIV and cytotoxicity have been reported previously.
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As shown in Table 1 , adenosine phosphonic acid 20 exhibited moderate anti-HIV activity with IC 50 = 28.3 μM. Also, nucleotide analogues 19, 21 and 23 did not show anti-HIV activity nor cytotoxicity up to 100 μM.
After demonstrating that adenine nucleoside analogue 20 slightly inhibits HIV-1 polymerase, we decide to study its properties computationally. Figure 3 shows the superposition of the calculated low energy conformers of 3, 4 and 20, underscoring the overall similarity of the three analogues and also highlighting the difference at purine base. Furthermore, the position of sterically bulky group such as phenyl group at 4'-position leads to the predicted difference in location of the phosphonic acid group. Figure 4 shows a pronounced difference in the 4'-cavity of the synthesized compound 20 compared to the selected nucleoside 3 bounds to the active site. The location of the wider cavity below 4'-substitents is formed by residue M184 and Y115 in the synthesized analogue 20 than the 4'-ethynyl-cpAP 3.
In summary, on the basis of potent anti-HIV activity of 4'-olefin branched nucleoside and 5'-norcarbocyclic nucleoside analogues, we have designed and successfully synthesized novel 4'-phenyl-5'-norcarbocyclic nucleoside analogues starting from propionaldehyde 5. 4'-Ethynyl analogue (3) and 4'-vinyl analogue (4) were found to inhibit RT with IC 50 = 0.14 μM and 0.65 μM, respectively. 4 Taking these data into account, the proposed 4'-pocket in the active site of RT is sensitive to changes in the 4'-substituent, especially when this involves increasing the van der Waals radius or possibly changes in the bulkiness. Compounds 20 and 23 exhibited weak anti-HIV activity, indicating that the bulky hydrophobic pocket such as phenyl group at 4'-position of 5'-norcarbocyclic nucleosides system are not perfect mimics for nucleoside analogues with small 4'-substituent. Therefore, the mechanisms of virus inhibition, that is, either phosphorylation or inhibition of RNA synthesis, might be impaired in these compounds.
Experimental Section
Melting points were determined on a Mel-temp II laboratory device and are uncorrected. NMR spectra were recorded on a JEOL 300 Fourier transform spectrometer (JEOL, Tokyo, Japan); chemical shifts are reported in parts per million (δ) and signals are reported as s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet) and dd (doublet of doublets). UV spectra were obtained on a Beckman DU-7 spectrophotometer (Beckman, South Pasadena, CA, USA). MS spectra were collected in electrospray ionization (ESI) mode. The elemental analyses were performed using a Perkin-Elmer 2400 analyzer (Perkin-Elmer, Norwalk, CT, USA). TLC was performed on Uniplates (silica gel) purchased from Analtech Co. (7558, Newark, DE, USA). All reactions were carried out under an atmosphere of nitrogen unless specified. Dry dichloromethane, benzene and pyridine were obtained by distillation from CaH 2 . Dry THF was obtained by distillation from Na and benzophenone immediately prior to use.
(±)-3-(t-Butyldimethylsilanyloxy)-1-phenylpropan-1-ol (6) . To a solution of 5 (4.01 g, 21.31 mmol) in dry THF (60 mL) was slowly added phenylmagnesium bromide (25.6 mL, 1.0 M solution in THF) at −10 o C and stirred 5 h at 0 o C under nitrogen. Saturated NH 4 Cl solution (25 mL) was added to the mixture, which was slowly warmed to rt. The mixture was further diluted with water (150 mL) and extracted with EtOAc (2 × 150 mL). The combined organic layer was washed with brine, dried over anhydrous MgSO 4 , filtered, and evaporated in vacuo. The residue was purified by silica gel column chromatography (EtOAc/hexane, 1:8) to give 6 (4.37 g, 77%) as a colorless oil: 3-(t-Butyldimethylsilanyloxy)-1-phenylpropan-1-one (7) . N-Chlorosuccinimide (NCS, 3.15 g, 23.5 mmol) was suspended in toluene (80 mL) and the mixture was cooled in an ice bath. Methyl sulfide (2.95 mL, 39.5 mmol) was added and a white precipitate formed immediately. The solution was attired for 30 min at 0 o C and then cooled to −20 o C. A solution of alcohol 6 (4.26 g, 16 mmol) in toluene (25 mL) was slowly added to the mixture. The mixture was kept under nitrogen for 3 h, whereupon TEA (3.3 mL, 23.5 mmol) was added, and the solution was allowed to warm to room temperature and was then stirred for 2 h. The mixture was extracted with ethyl acetate, washed with 1 N HCl, water and brine, dried over anhydrous MgSO 4 , filtered, and evaporated in vacuo. The residue was purified by silica gel column chromatography (EtOAc/hexane, 1:12) to give 7 (3.3 g, 78%) as a colorless oil: added to the mixture, which was slowly warmed to rt. The mixture was further diluted with water (120 mL) and extracted with EtOAc (2 × 100 mL). The combined organic layer was washed with brine, dried over anhydrous MgSO 4 (±)-Benzoic Acid 3-Hydroxy-3-phenylpent-4-enyl Ester (10). To a solution of 9 (1.25 g, 7.01 mmol) in anhydrous pyridine (12 mL) was added benzoyl chloride (1.08 g, 7.71 mmol) and DMAP (43 mg, 0.355 mmol) at 0 ºC. The reaction mixture was stirred overnight at rt. The reaction mixture was quenched with saturated NaHCO 3 solution (10 mL), stirred for 20 minutes and concentrated under reduced pressure. The residue was poured into water (100 mL) and extracted with EtOAc (100 mL) twice. The combined organic layer was washed with brine, dried over MgSO 4 , filtered, and concentrated. The residue was purified by silica gel column chromatography (EtOAc/hexane, 1:5) to give 10 (1.44 g, 73%) as a colorless syrup: (±)-Benzoic Acid 3-(t-Butyldimethylsilanyloxy)-3-phenylpent-4-enyl Ester (11) . To a solution of 10 (1.6 g, 5.66 mmol) in anhydrous CH 2 Cl 2 (12 mL) was added 2,6-lutidine (2.42 g, 22.6 mmol) at 0 ºC. t-Butyldimethylsilyl trifluomethanesulfonate (TBDMSOTf) (2.24 g, 8.49 mmol) was added to this mixture and the reaction mixture was stirred overnight at rt and quenched with cold H 2 O (10 mL). The mixture was diluted with water (80 mL) and extracted with EtOAc (2 × 80 mL). Combined organic layer was washed with brine, dried over MgSO 4 , filtered, and concentrated. The residue was purified by silica gel column chromato- (±)-3-(t-Butyldimethylsilanyloxy)-3-phenylpent-4-enal (13). To a stirred solution of oxalyl chloride (190 mg, 1.5 mmol) in CH 2 Cl 2 (11 mL) was added a solution of DMSO (234 mg, 3.0 mmol) in CH 2 Cl 2 (5.0 mL) dropwise at -78 ºC. The resulting solution was stirred at -78 ºC for 10 min under nitrogen, and a solution of alcohol 12 (219 mg, 0.75 mmol) in CH 2 Cl 2 (12 mL) was added dropwise. The mixture was stirred at -78 ºC for 30 min and TEA (607 mg, 6.0 mmol) was added. The resulting mixture was warmed to 0 ºC and stirred for 30 min under nitrogen. H 2 O (17 mL) was added, and the solution was stirred at room temperature for 30 min. The mixture was further diluted with water (110 mL) and then extracted with EtOAc (2 × 110 mL). The combined organic layer was washed with brine, dried over anhydrous MgSO 4 and filtered. The filtrate was concentrated in vacuo and the residue was purified by silica gel column chromatography (EtOAc/hexane, 1:12) to give aldehyde compound 13 (198 mg, 91%) as a colorless oil: (±)-3R and 3S,5S)-5-(t-Butyldimethylsilanyloxy)-5-phenyl-hepta-1,6-dien-3-ol (14) . Divinyl analogue 14 was synthesized from aldehyde 13 by the similar procedure as described for 8 as a diastereomeric mixture: yield 74%; Molecular Modeling. The low energy conformations are calculated by quantum mechanics method using B3LYP/6-31G**. For modeling of the complex form, the structure of the ternary complex of HIV-1 RT (PDB code 1RTD) was used as the starting point. The dTTP of the active site was modified into our anti-HIV-1 RT agent analogues. All template positions of the enzyme are fixed except M184 and Y115 so called 'primer grip' in the minimization of the complex. For maintaining the bind site, Mg ions and diphosphophosphonates group are also fixed. Therefore, the agents and primer grip region are flexible. All modeling studies and the calculations are performed by the modeling package Spartan software. For minimization of the complex, molecular mechanics force field such as MMFF was used.
